Ken-ichi Kusakabe is a seasoned drug discovery leader and medicinal chemist with 20 years of experience at Shionogi & Co. , Ltd. , where he serves as Director and Head of Neuroscience Chemistry. He specializes in CNS drug design for neuroscience, immunology, and oncology, holding a Doctorate in Pharmaceutical Sciences from Kumamoto University.
He is passionate about advancing drug discovery, often sharing his teams research on novel approaches to CNS drug design and Alzheimers research with the broader scientific community. He is also focused on team building and recruiting top talent in medicinal chemistry.
His collaborative work with Janssen led to the discovery of Atabecestat, a BACE1 inhibitor that advanced to Phase 2b/3 clinical trials for Alzheimers disease.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.